An experimental lung cancer drug called ivonescimab, developed by Akeso and Summit Therapeutics, has shown promise in clinical trials. Recent results indicate that it can reduce the risk of death by 34% when combined with chemotherapy for patients with squamous non-small-cell lung cancer. These findings were revealed ahead of a presentation at the American Society of Clinical Oncology’s annual meeting.
In the trial, patients treated with ivonescimab had a median survival of 27.9 months compared to 23.7 months for those receiving standard treatment. Dr. Suresh Ramalingam, from Emory University, praised the results but cautioned that the trial’s exclusive focus on a Chinese population raises questions about how the results will apply globally.
Ivonescimab targets PD-1 and VEGF, proteins that help cancer cells evade the immune system. This dual action has sparked excitement in the oncology field. Experts see potential in ivonescimab as a successor to Merck’s Keytruda, a leading cancer treatment. However, some remain skeptical, recalling other promising drugs that didn’t deliver.
Summit Therapeutics has seen its stock surge nearly 600% since promising results emerged from earlier trials. Yet, the recent month has seen fluctuations, reflecting investor concerns about how effective the drug may be in diverse populations.
The trial data also highlighted the safety of ivonescimab. While about 25% of patients experienced some bleeding, only a small percentage faced severe cases. This safety profile is crucial, especially because tumor locations in squamous lung cancer can lead to risky complications.
With continuous advancements in cancer treatment, the landscape is changing. PD-1 and VEGF drugs are part of a new wave of therapies that can offer hope where traditional treatments might not work.
In the broader context of oncology, the licensing of PD-1 drugs alone reached $30 billion last year, nearly doubling the previous high. This indicates strong interest and investment in new treatments. However, with increasing competition from emerging therapies, including antibody drug conjugates, it’s uncertain whether ivonescimab will achieve the same level of widespread adoption as Keytruda.
Dr. Marjorie Green from Merck noted that having multiple treatment options is beneficial for patients, marking a promising shift in lung cancer therapy. As more data emerges from ongoing studies, the outlook for advanced lung cancer treatments continues to evolve.
For more information on cancer treatment advancements, you can refer to reliable sources such as Cancer Research UK or the American Cancer Society.
Source link
Health care industry,Biotech and Pharmaceuticals,China,Summit Therapeutics Inc,Merck & Co Inc,Social issues,Pfizer Inc,business news
